Sandra Abrevaya
About Sandra Abrevaya
Sandra Abrevaya is the co-founder and CEO of Synapticure, known for her advocacy in neurodegenerative disease care and research, particularly ALS, from which she has been suffering for over six years.
Sandra Abrevaya, Co-Founder and CEO of Synapticure
Sandra Abrevaya is the Co-Founder and Chief Executive Officer of Synapticure. She has been actively involved in leading the company alongside Brian Wallach. Under her leadership, the organization focuses on providing accessible, compassionate care to patients, their caregivers, and loved ones. Sandra's professional role emphasizes advocating for better access to care and increased support for caregivers.
Sandra Abrevaya Living with ALS
Sandra Abrevaya has been living with ALS for more than six years. Her personal experience with the neurodegenerative disease has significantly influenced her advocacy and professional pursuits. Sandra's lived experience with ALS brings a unique perspective to her work at Synapticure, driving the mission to democratize access to exceptional care and put patients first.
Synapticure Co-Founders: Sandra Abrevaya and Brian Wallach
Sandra Abrevaya co-founded Synapticure with Brian Wallach. Their partnership is driven by a shared commitment to improving the lives of those affected by neurodegenerative diseases. The duo's efforts have been highlighted in the documentary 'No Ordinary Campaign,' which details their journey with ALS and their advocacy work. Together, they aim to provide accessible, specialized care through Synapticure.
Sandra Abrevaya's Advocacy Work
Sandra Abrevaya is a dedicated advocate for better access to care for patients with neurodegenerative diseases and increased support for their caregivers. Her advocacy has taken her to the White House, where she shared her story of resilience and pushed for policies supporting those affected by such conditions. Sandra's efforts also include Synapticure's announcement of The Michael J. Fox Foundation as their newest advisor, aiming to improve access to specialty care and accelerate Parkinson’s research.